• 1
    Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007; 62:35966.
  • 2
    Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998; 81:4638.
  • 3
    US Department of Health and Human Services. Management of allergic and nonallergic rhinitis: summary. Evidence report/technical assessment number 54. Rockville, MD: Agency for Healthcare Research and Quality, 2002.
  • 4
    McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994; 73:359.
  • 5
    Nimmagadda SR, Evans R III. Allergy: etiology and epidemiology. Pediatr Rev 1999; 20:11115.
  • 6
    Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63 (Suppl. 86):8160.
  • 7
    Garcia-Mozo H, Galan C, Jato V et al. Quercus pollen season dynamics in the Iberian peninsula: response to meteorological parameters and possible consequences of climate change. Ann Agric Environ Med 2006; 13:20924.
  • 8
    Frei T, Gassner E. Climate change and its impact on birch pollen quantities and the start of the pollen season an example from Switzerland for the period 1969–2006. Int J Biometeorol 2008; 52:66774.
  • 9
    Emberlin J, Detandt M, Gehrig R, Jaeger S, Nolard N, Rantio-Lehtimäki A. Responses in the start of Betula (birch) pollen seasons to recent changes in spring temperatures across Europe. Int J Biometeorol 2002; 46:15970.
  • 10
    Fitter AH, Fitter RS. Rapid changes in flowering time in British plants. Science 2002; 296:168991.
  • 11
    Wayne P, Foster S, Connolly J, Bazzaz F, Epstein P. Production of allergenic pollen by ragweed (Ambrosia artemisiifolia L.) is increased in CO2-enriched atmospheres. Ann Allergy Asthma Immunol 2002; 88:27982.
  • 12
    Ziska LH, Gebhard DE, Frenz DA, Faulkner S, Singer BD, Straka JG. Cities as harbingers of climate change: common ragweed, urbanization, and public health. J Allergy Clin Immunol 2003; 111:2905.
  • 13
    Stach A, Emberlin J, Smith M, Adams-Groom B. Factors that determine the severity of Betula spp. pollen seasons in Poland (Poznań and Krakow) and the United Kingdom (Worcester and London). Int J Biometeorol 2008; 52:31121.
  • 14
    Emberlin J, Smith M, Close R, Adams-Groom B. Changes in the pollen seasons of the early flowering trees Alnus spp. and Corylus spp. in Worcester, United Kingdom, 1996–2005. Int J Biometeorol 2007; 51:18191.
  • 15
    D'Amato G. Environmental urban factors (air pollution and allergens) and the rising trends in allergic respiratory diseases. Allergy 2002; 57 (Suppl. 72):303.
  • 16
    Van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis: European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:11634.
  • 17
    Demoly P, Allaert FA, Lecasble M, Bousquet J; PRAGMA. Validation of the classification of ARIA (Allergic Rhinitis and its Impact on Asthma). Allergy 2003; 58:6725.
  • 18
    Ciprandi G, Buscaglia S, Pesce G et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995; 96:9719.
  • 19
    Connell JT. Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. J Allergy 1969; 43:3344.
  • 20
    Juliusson S, Bende M. Priming effect of a birch pollen season studied with laser Doppler flowmetry in patients with allergic rhinitis. Clin Allergy 1988; 18:6158.
  • 21
    Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol 1989; 84:492501.
  • 22
    Naito K, Ishihara M, Senoh Y, Takeda N, Yokoyama N, Iwata S. Seasonal variations of nasal resistance in allergic rhinitis and environmental pollen counts. II. Efficacy of preseasonal therapy. Auris Nasus Larynx 1993; 20:318.
  • 23
    Koh YY, Lim HS, Min KU, Min YG. Airways of allergic rhinitics are ‘primed’ to repeated allergen inhalation challenge. Clin Exp Allergy 1994; 24:33746.
  • 24
    Assing K, Bodtger U, Poulsen LK, Malling HJ. Grass pollen symptoms interfere with the recollection of birch pollen symptoms – a prospective study of suspected, asymptomatic skin sensitization. Allergy 2007; 62:3737.
  • 25
    Graft D, Aaronson D, Chervinsky P et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996; 98:72431.
  • 26
    Marazzi P, Nolop K, Lutsky BN et al. Prophylactic use of once-daily mometasone furoate (Nasonex) aqueous nasal spray in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1997; 99 (Pt 2):S440.
  • 27
    Storms WW. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. Ann Allergy Asthma Immunol 2003; 91:13140.
  • 28
    Pitsios C, Papadopoulos D, Kompoti E et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:6738.
  • 29
    Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006; 36:689703.
  • 30
    Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol 1999; 104:S1327.
  • 31
    Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:307.
  • 32
    Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 1999; 103:11739.
  • 33
    Illi S, Von Mutius E, Lau S, Niggemann B, Grüber C, Wahn U, for the Multicentre Allergy Study (MAS) group. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 2006; 368:76370.
  • 34
    Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99:S76372.
  • 35
    Canonica GW. Introduction to nasal and pulmonary allergy cascade. Allergy 2002; 57 (Suppl. 75):812.
  • 36
    Dahl R. Early- and late-phase reaction in the bronchi and the nose. In: MygindN, PipkornJ, DahlR, eds. Rhinitis and asthma. Copenhagen: Munksgaard, 1990:20312.
  • 37
    Bousquet J, Van Cauwenberge P, Khaltaev N, for the ARIA Workshop Group and the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 5):S147334.
  • 38
    Bachert C, Hauser U, Prem B, Rudack C, Ganzer U. Proinflammatory cytokines in allergic rhinitis. Eur Arch Otorhinolaryngol 1995; 252 (Suppl. 1):S449.
  • 39
    Montefort S, Feather IH, Wilson SJ et al. The expression of leukocyte-endothelial adhesion molecules is increased in perennial allergic rhinitis. Am J Respir Cell Mol Biol 1992; 7:3938.
  • 40
    Wang D, Clement P, Smitz J, De Waele M, Derde MP. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995; 106:27885.
  • 41
    Miyahara S, Miyahara N, Matsubara S, Takeda K, Koya T, Gelfand EW. IL-13 is essential to the late-phase response in allergic rhinitis. J Allergy Clin Immunol 2006; 118:111016.
  • 42
    Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Bagnasco M, Canonica GW. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects: relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994; 150:16539.
  • 43
    Pastorello EA, Riario-Sforza GG, Incorvaia C, Segala M, Fumagalli M, Gandini R. Comparison of rhinomanometry, symptom score, and inflammatory cell counts in assessing the nasal late-phase reaction to allergen challenge. J Allergy Clin Immunol 1994; 93:8592.
  • 44
    Milanese M, Ricca V, Canonica GW, Ciprandi G. Eosinophils, specific hyperreactivity and occurrence of late phase reaction in allergic rhinitis. Eur Ann Allergy Clin Immunol 2005; 37:710.
  • 45
    Linder A, Venge P, Deuschl H. Eosinophil cationic protein and myeloperoxidase in nasal secretion as markers of inflammation in allergic rhinitis. Allergy 1987; 42:58390.
  • 46
    Niederberger V, Ring J, Rakoski J et al. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 2007; 142:13344.
  • 47
    Connell JT. Quantitative intranasal pollen challenge. II. Effect of daily pollen challenge, environmental pollen exposure, and placebo challenge on the nasal membrane. J Allergy 1968; 41:12339.
  • 48
    Passalacqua G, Ciprandi G, Canonica GW. The nose–lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol 2001; 1:713.
  • 49
    Montoro J, Sastre J, Jáuregui I et al. Allergic rhinitis: continuous or on demand antihistamine therapy? J Investig Allergol Clin Immunol 2007; 17 (Suppl. 2):217.
  • 50
    Ricca V, Landi M, Ferrero P et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 105:547.
  • 51
    Knani J, Campbell A, Enander I, Peterson CG, Michel FB, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992; 90:8809.
  • 52
    Juliusson S, Pipkorn U, Karlsson G, Enerbäck L. Mast cells and eosinophils in the allergic mucosal response to allergen challenge: changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol 1992; 90:898909.
  • 53
    Roquat A, Ihre E, Van Hage-Hamsten M, Halldén G, Zetterström O. Allergen-induced inflammation in the nose: a comparison of acute and repeated low-dose allergen exposure. Allergy 1996; 51:428.
  • 54
    Bachert C, Van Kempen M, Van Cauwenberge P. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999; 118:3759.
  • 55
    Canonica GW. Introduction: expanding the anti-allergy therapeutic horizon. Allergy 2002; 57 (Suppl. 75):57.
  • 56
    Huovinen E, Kaprio J, Laitinen LA, Koskenvuo M. Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and their relation to hay fever and chronic bronchitis. Chest 1999; 115:92836.
  • 57
    Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:41925.
  • 58
    Greisner WA, Settipane RJ, Settipane GA. The course of asthma parallels that of allergic rhinitis: a 23-year follow-up study of college students. Allergy and Asthma Proc 2000; 21:3716.
  • 59
    Rzehak P, Schoefer Y, Wichmann HE, Heinrich J. A prospective study on the association between hay fever among children and incidence of asthma in East Germany. Eur J Epidemiol 2008; 23:1722.
  • 60
    Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107:46976.
  • 61
    Braunstahl GJ, Overbeek SE, Fokkens WJ et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001; 164:85865.
  • 62
    Zhang QG, Zheng DS, Yao YT, Zhang XH, Yu HL, Liang DP. Relationship between levels of intercellular adhesion molecule-1, interleukin-6 and airway hyperresponsiveness in patients with allergic rhinitis. Zhonghua Er Bi Yan Hou Ke Za Zhi 2004; 39:61720.
  • 63
    Beeh KM, Beier J, Kornmann O, Meier C, Taeumer T, Buhl R. A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clin Exp Allergy 2003; 33:47582.
  • 64
    Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:42534.
  • 65
    Greve JM, Davis G, Meyer AM et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56:83947.
  • 66
    Johnston SL, Pattemore PK, Sanderson G et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time–trend analysis. Am J Respir Crit Care Med 1996; 154 (3 pt 1):65460.
  • 67
    Passalacqua G, Ciprandi G, Pasquali M, Guerra L, Canonica GW. An update on the asthma–rhinitis link. Curr Opin Allergy Clin Immunol 2004; 4:17783.
  • 68
    Gorska-Ciebiada M, Ciebiada M, Gorska MM, Gorski P, Grzelewska-Rzymowska I. Intercellular adhesion molecule 1 and tumor necrosis factor alpha in asthma and persistent allergic rhinitis: relationship with disease severity. Ann Allergy Asthma Immunol 2006; 97:6672.
  • 69
    Linneberg A, Henrik Nielsen N, Frølund L, Madsen F, Dirksen A, Jørgensen T, for the Copenhagen Allergy Study. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002; 57:104852.
  • 70
    Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:5762.
  • 71
    Passalacqua G, Canonica GW. Impact of rhinitis on airway inflammation: biological and therapeutic implications. Respir Res 2001; 2:3203.
  • 72
    Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Exp Opin Investig Drugs 2002; 11:25973.
  • 73
    Vignola AM, Crampette L, Mondain M et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995; 50:2003.
  • 74
    Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997; 27:116774.
  • 75
    Zhao Y, Leung PC, Woo KS et al. Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1). Inflamm Res 2004; 53:66449.
  • 76
    Mullol J, Roca-Ferrer J, Alobid I et al. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy 2006; 36:528.
  • 77
    Jinquan T, Reimert CM, Deleuran B, Zachariae C, Simonsen C, Thestrup-Pedersen K. Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes. J Allergy Clin Immunol 1995; 95 (5 pt 1):97986.
  • 78
    Pasquali M, Baiardini I, Rogkakou A et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006; 36:11617.
  • 79
    Ciprandi G, Tosca MA, Milanese M, Ricca V. Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. Eur Ann Allergy Clin Immunol 2004; 36:23740.
  • 80
    Fujikura T. New therapeutic approaches to the treatment of nasal allergy: antiinflammatory effects of H1 receptor antagonists. Drugs Today (Barc) 2001; 37:45561.
  • 81
    Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79:50711.
  • 82
    Ciprandi G, Ricca V, Passalacqua G et al. Seasonal rhinitis and azelastine: long- or short-term treatment? J Allergy Clin Immunol 1997; 99:3017.
  • 83
    Ferreira MB, Santos MC, Pregal AL et al. Effect of specific immunotherapy versus loratadine on serum adhesion molecules. Allerg Immunol (Paris) 2001; 33:31922.
  • 84
    Lauriello M, Muzi P, Di Rienzo L, Di Stanislao C, Tirelli GC, Bologna M. A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol Ital 2005; 25:28491.
  • 85
    Dizdar EA, Sekerel BE, Keskin O et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol 2007; 71:8439.
  • 86
    Canonica GW, Fumagalli F, Guerra L et al. Global Allergy and Asthma European Network. Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Curr Med Res Opin 2008; 24:282939.
  • 87
    Ciprandi G, Ricca V, Tosca M, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy 1999; 54:35865.
  • 88
    Okubo K, Baba K. Therapeutic effect of montelukast a cysteinyl leukotriene receptor 1 antagonist, on Japanese patients with seasonal allergic rhinitis. Allergol Int 2008; 57:24755.
  • 89
    Price D, Bond C, Bouchard J et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J 2006; 15:5870.
  • 90
    Ciprandi G, Frati F, Marcucci F et al. Nasal cytokine modulation by montelukast in allergic children: a pilot study. Eur Ann Allergy Clin Immunol 2003; 35:2959.
  • 91
    Nayak AS, Philip G, Lu S, Malice MP, Reiss TF, for the Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88:592600.
  • 92
    Mygind N, Nielsen LP, Hoffmann HJ et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 2001; 108 (Suppl. 1):S1625.
  • 93
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317:16249.
  • 94
    Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89:47984.
  • 95
    Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002; 15:3550.
  • 96
    Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000; 55:60313.
  • 97
    Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003; 111:322.
  • 98
    Umland SP, Nahrebne DK, Razac S et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997; 100:51119.
  • 99
    Frieri M, Therattil J, Chavarria V et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1998; 81 (5 pt 1):4317.
  • 100
    Ciprandi G, Tosca MA, Passalacqua G, Canonica GW. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann Allergy Asthma Immunol 2001; 86:4338.
  • 101
    Erin EM, Leaker BR, Zacharasiewicz AS et al. Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. Allergy 2005; 60:15249.
  • 102
    Kleinjan A, Holm AF, Dijkstra MD et al. Preventive treatment of intranasal fluticasone propionate reduces cytokine mRNA expressing cells before and during a single nasal allergen provocation. Clin Exp Allergy 2000; 30:147685.
  • 103
    Wright ED, Christodoulopoulos P, Small P, Frenkiel S, Hamid Q. Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids. Laryngoscope 1999; 109:5516.
  • 104
    Erin EM, Zacharasiewicz AS, Nicholson GC et al. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005; 35:160814.
  • 105
    Ciprandi G, Ricca V, Passalacqua G, Fasolo A, Canonica GW. Intranasal fluticasone propionate reduces ICAM-1 on nasal epithelial cells both during early and late phase after allergen challenge. Clin Exp Allergy 1998; 28:2939.
  • 106
    Holm A, Dijkstra M, Kleinjan A et al. Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge. J Allergy Clin Immunol 2001; 107:62733.
  • 107
    Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal–ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009; 123:13428.
  • 108
    Lange B, Lukat KF, Rettig K, Holtappels G, Bachert C. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:27282.
  • 109
    Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ, Lichtenstein LM. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988; 81:5809.
  • 110
    Mullol J, Xaubet A, López E, Roca-Ferrer J, Picado C. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 1995; 50:2704.
  • 111
    Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001; 23:133954.
  • 112
    Martin BG, Ratner PH, Hampel FC et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007; 28:21625.
  • 113
    Pullerits T, Praks L, Sjöstrand M, Rak S, Skoogh BE, Lötvall J. An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season. J Allergy Clin Immunol 1997; 100:6015.
  • 114
    Mastrandrea F, Coradduzza G, De Vita L et al. CD34+ cells in peripheral blood of healthy human beings and allergic subjects: clue to acute and minimal persistent inflammation. Allergol Immunopathol (Madr) 2002; 30:20917.
  • 115
    Sergejeva S, Malmhäll C, Lötvall J, Pullerits T. Increased number of CD34+ cells in nasal mucosa of allergic rhinitis patients: inhibition by a local corticosteroid. Clin Exp Allergy 2005; 35:348.
  • 116
    Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987; 316:150610.
  • 117
    Baroody FM, Cruz AA, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM. Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. J Allergy Clin Immunol 1992; 90:3736.
  • 118
    Wang D, Smitz J, De Waele M, Clement P. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 1997; 114:18592.
  • 119
    Karaman O, Günbay A, Uzuner N et al. The comparison of the efficacy of fluticasone propionate with cetirizine in perennial allergic rhinitis. Allergol Immunopathol (Madr) 2001; 29:559.
  • 120
    Ahlström Emanuelsson C, Andersson M, Persson CG, Thorsson L, Greiff L. Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis. Respir Med 2007; 101:110612.
  • 121
    Konno A, Yamakoshi T, Terada N, Fujita Y. Mode of action of a topical steroid on immediate phase reaction after antigen challenge and nonspecific nasal hyperreactivity in nasal allergy. Int Arch Allergy Immunol 1994; 103:7987.
  • 122
    Holm AF, Godthelp T, Fokkens WJ et al. Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis. Clin Exp Allergy 1999; 29:135666.
  • 123
    Fokkens WJ, Godthelp T, Holm AF, Klein-Jan A. Local corticosteroid treatment: the effect on cells and cytokines in nasal allergic inflammation. Am J Rhinol 1998; 12:216.
  • 124
    Till SJ, Jacobson MR, O'Brien F et al. Recruitment of CD1a+ Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy. Allergy 2001; 56:12631.
  • 125
    Corren J, Manning BE, Thompson SF. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004; 113:41519.
  • 126
    Bousquet J, Chanal I, Alquié MC et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray: a multicenter, double-blind, double-dummy, parallel-group study. Allergy 1993; 48:32733.
  • 127
    Morelli MC, Bordonaro S, Hedbys L, Romagnani S, for the Italian Study Group. Effect of pre-seasonal and seasonal treatment with budesonide topical nasal powder in patients with seasonal allergic rhinitis. Allergol Int 1996; 45:1517.
  • 128
    Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:94955.
  • 129
    New Zealand Medicines and Medical Devices Safety Authority. Tilarin Nasal Spray Data Sheet. Available at (accessed 10 October 2008).
  • 130
    Schering Corporation. Nasonex [package insert]. Kenilworth, NJ: Schering Corporation, 2005.
  • 131
    Schering Corporation. and Side Effects. Available at: (accessed 28 August 2008).